Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis
- 1 February 2006
- journal article
- Published by American Society of Hematology in Blood
- Vol. 107 (3), 1227-1229
- https://doi.org/10.1182/blood-2005-08-3253
Abstract
Extensive cardiac amyloid deposition in systemic AL amyloidosis is associated with a grave prognosis. Heart transplantation is rarely performed because of the systemic and progressive nature of the disease. Patients with severe cardiac amyloid infiltration are ineligible for the preferred treatment of melphalan chemotherapy with stem cell transplantation (SCT) rescue because of the high risk for treatment-related mortality. Heart transplantation followed by SCT was performed in 5 patients with AL amyloidosis and predominant cardiomyopathy. Patients were followed up for a median of 95 months (range, 37-118 months) from diagnosis. At censor, 3 of 5 patients were well without evidence of intracardiac or extracardiac amyloid accumulation, and median overall survival by Kaplan-Meier estimate was not reached. Two patients died of progressive amyloidosis 33 and 90 months after heart transplantation after relapse of their underlying plasma cell dyscrasia. Heart transplantation followed by SCT is feasible in selected patients with cardiac AL amyloidosis and may confer substantial survival benefit.Keywords
This publication has 17 references indexed in Scilit:
- Cardiac transplantation for amyloid heart disease: The United Kingdom experienceThe Journal of Heart and Lung Transplantation, 2004
- Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapyBritish Journal of Haematology, 2003
- Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL)Bone Marrow Transplantation, 2000
- High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplantBone Marrow Transplantation, 1999
- A review of the amyloidoses that infiltrate the heartClinical Cardiology, 1998
- Serum amyloid P component scintigraphy in familial amyloid polyneuropathy: regression of visceral amyloid following liver transplantationEuropean Journal of Nuclear Medicine and Molecular Imaging, 1998
- Prognostic factors for survival and response after high‐dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patientsBritish Journal of Haematology, 1998
- A Trial of Three Regimens for Primary Amyloidosis: Colchicine Alone, Melphalan and Prednisone, and Melphalan, Prednisone, and ColchicineNew England Journal of Medicine, 1997
- Treatment of 100 patients with primary amyloidosis: A randomized trial of melphalan, prednisone, and colchicine versus colchicine onlyAmerican Journal Of Medicine, 1996
- Evaluation of Systemic Amyloidosis by Scintigraphy with123I-Labeled Serum Amyloid P ComponentNew England Journal of Medicine, 1990